Efficacy of the new lantibiotic NAI-107 in experimental infections induced by multidrug-resistant gram-positive pathogens

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 4, 2011, Pages 1671-1676

  Jabés, Daniela ^a,b   Brunati, Cristina ^a,b   Candiani, GianPaolo ^b   Riva, Simona ^b   Romanó, Gabriella ^b   Donadio, Stefano ^a  

^a NAICONS Srl   (Italy)

^b Vicuron Pharmaceuticals   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LANTIBIOTIC; LINEZOLID; NAI 107; PENICILLIN G; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG PROTEIN BINDING; ENDOCARDITIS; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FEMALE; GLYCOPEPTIDE INTERMEDIATE STAPHYLOCOCCUS AUREUS; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; GRANULOMA; IMMUNE STATUS; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RAT; STREPTOCOCCUS PNEUMONIAE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIOCINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENDOCARDITIS; FEMALE; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; RATS; RATS, SPRAGUE-DAWLEY; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN RESISTANCE;

EID: 79953242162     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01288-10     Document Type: Article

References (29)

1. Anonymous. 2010. New antimicrobial agents approved by the U. S. Food and Drug Administration from 2007 to 2009 and new indications for previously approved agents. Antimicrob. Agents Chemother. 54:4033-4035.
2. Anonymous. 2009. Urgently needed: new antibiotics. Lancet 374:1868.
3. Baddour, L. M., et al. 2005. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111:394-434.
4. Boakes, S., A. N. Appleyard, J. Cortés, and M. J. Dawson. 2010. Organization of the biosynthetic genes encoding deoxyactagardine B (DAB), a new lantibiotic produced by Actinoplanes liguriae NCIMB41362. J. Antibiot. (Tokyo). 63:351-358.
5. Bossaer, J. B., P. D. Hall, and E. Garrett-Mayer. 2010. Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE. Support Care Cancer 19:231-237.
6. Candiani, G. P., M. Abbondi, G. Romano, and F. Parenti. 1999. In vitro and in vivo antibacterial activity of BI397, a new semi-synthetic glycopeptide antibiotic. J. Antimicrob. Chemother. 44:179-192.
7. Castiglione, F., et al. 2008. Determining the structure and mode of action of microbisporicin, a potent lantibiotic active against multiresistant pathogens. Chem. Biol. 15:22-31.
8. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th ed. CLSI document M7-A7. CLSI, Wayne, PA.
9. Dalhoff, A. 1986. The granuloma pouch, p. 123-137. In O. Zak and M. A. Sande (ed.), Experimental models in antimicrobial chemotherapy. Academic Press, London, United Kingdom.
10. Donadio, S., S. Maffioli, P. Monciardini, M. Sosio, and D. Jabes. 2010. Antibiotic discovery in the 21st century: current trends and future perspectives. J. Antibiot. (Tokyo) 63:423-430.
11. Finney, D. J. 1952. The Spearman-Kärber method. p. 524-530. In D. J. Finney (ed.) Statistical method in biological assay. Charles Griffin & Company Ltd., London, United Kingdom.
12. Fowler, V. G., Jr., et al. 2005. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293:3012-3021.
13. Furtado, G. H., and D. P. Nicolau. 2010. Overview perspective of bacterial resistance. Expert Opin. Ther. Pat. 20:1273-1276.
14. Higgins, D. L., et al. 2005. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49:1127-1134.
15. Infectious Diseases Society of America. 2010. The 10 x 20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis. 50:1081-1083.
16. Jabes, D., et al. 2004. Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model. Antimicrob. Agents Chemother. 48:1118-1123.
17. Jabes, D., C. Brunati, P. Guglierame, and S. Donadio. 2009. In vitro antibacterial profile of the new lantibiotic NAI-107, abstr. F1-1502. Progr. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother.
18. Jabes, D., G. Candiani, G. Romano, C. Brunati, and S. Riva. 2009. NAI-107: SUperior efficacy in animal models of MDR Gram-positive infection, abstr. F1-1503. Progr. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother.
19. Jabes, D., G. Candiani, G. Romano, C. Brunati, and S. Riva. 2009. NAI-107: superior efficacy in MRSA rat endocarditis, abstr. F1-1221. Progr. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother.
20. Jabes, D., and S. Donadio. 2010. Strategies for the isolation and characterization of antibacterial lantibiotics. Methods Mol. Biol. 618:31-45.
21. Kamboj, M., et al. 2010. The changing epidemiology of vancomycin-resistant enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Biol. Blood Marrow Transplant. 16:1576-1581.
22. Klevens, R. M., et al. 2006. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin. Infect. Dis. 42:389-391.
23. Olivier, C. N., R. K. Blake, L. L. Steed, and C. D. Salgado. 2008. Risk of vancomycin-resistant enterococcus (VRE) bloodstream infection among patients colonized with VRE. Infect. Control Hosp. Epidemiol. 29:404-409.
24. Theuretzbacher, U. 2009. Future antibiotics scenarios: is the tide starting to turn? Int. J. Antimicrob. Agents 34:15-20.
25. Sobel, J. 1992. Nosocomial infective endocarditis, p. 316. In D. Kaye (ed.), Infective endocarditis, 2nd ed. Raven Press Ltd., New York, NY.
26. Rubinstein, E., et al. 2003. Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob. Agents Chemother. 47:1824-1831.
27. Voorn, G. P., J. Kuyvenhoven, W. H. Goessens, W. C. Schmalbauer, and P. H. Broeders. 1994. Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis, with vancomycin, teicoplanin, and daptomycin. Antimicrob. Agents Chemother. 38:487-493.
28. Wenzel, R. P. 2004. The antibiotic pipeline: challenges, costs, and values. N. Engl. J. Med. 351:523-526.
29. Willey, J. M., and W. A. van der Donk. 2007. Lantibiotics: peptides with diverse structure and function. Annu. Rev. Microbiol. 61:477-501.